The chemical class of CPA1 Inhibitors encompasses a range of compounds designed to modulate the activity of Carboxypeptidase A1 (CPA1), an enzyme playing a crucial role in protein digestion. These inhibitors are characterized by their diverse modes of action, each aimed at interfering with the enzymatic function of CPA1. The design and study of CPA1 inhibitors are grounded in the understanding of the enzyme's structure and function, particularly its role in cleaving amino acids from the C-terminal of proteins and peptides. This group of inhibitors operates primarily by targeting the active site of CPA1, where they either compete with natural substrates for binding or alter the enzyme's conformation, thereby inhibiting its activity. Another subset of these inhibitors focuses on the zinc ion, a vital cofactor in the enzymatic process of CPA1. By chelating this metal ion, these inhibitors render the enzyme inactive, demonstrating the critical nature of metal ions in the function of metalloenzymes like CPA1.
The development of CPA1 inhibitors represents a significant stride in the field of enzyme inhibition and provides valuable insights into the regulation of proteolytic enzymes. By understanding the mechanisms through which these inhibitors act, researchers can explore the enzyme's role beyond its primary function in protein digestion. This includes studying the enzyme's structure-activity relationship, which is vital for elucidating how CPA1 recognizes and interacts with its substrates and inhibitors. Moreover, the study of CPA1 inhibitors contributes to the broader understanding of enzymatic regulation and inhibition. These inhibitors serve as crucial tools for probing the dynamics of enzymatic action and the interactions between enzymes and small molecules. In essence, the CPA1 inhibitors are not just about impeding an enzyme's function; they offer a window into the complex world of enzymatic processes and the potential to explore new aspects of biochemistry and molecular biology. Through these inhibitors, the nuanced mechanisms of enzyme action can be unraveled, offering a deeper understanding of how enzymes are regulated and how they can be modulated for various purposes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1,10-Phenanthroline | 66-71-7 | sc-255888 sc-255888A | 2.5 g 5 g | $23.00 $32.00 | ||
Might inhibit CPA1 by directly removing its essential zinc cofactor. | ||||||
Gabexate mesylate | 56974-61-9 | sc-215066 | 5 mg | $100.00 | ||
Might inhibit CPA1 directly by interfering with its protease activity. | ||||||
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $84.00 $306.00 $1104.00 | 30 | |
Could inhibit CPA1 by directly affecting its protease activity. | ||||||
Bestatin | 58970-76-6 | sc-202975 | 10 mg | $131.00 | 19 | |
Known as an aminopeptidase inhibitor, could directly inhibit CPA1. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
Could inhibit CPA1 by directly impacting its enzymatic activity. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Might inhibit CPA1 by directly interfering with its protease function. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $112.00 $408.00 $3000.00 | 51 | |
A broad-spectrum protease inhibitor that could directly inhibit CPA1. | ||||||
Benzamidine | 618-39-3 | sc-233933 | 10 g | $292.00 | 1 | |
Could possibly inhibit CPA1 as a serine protease inhibitor. | ||||||
AEBSF hydrochloride | 30827-99-7 | sc-202041 sc-202041A sc-202041B sc-202041C sc-202041D sc-202041E | 50 mg 100 mg 5 g 10 g 25 g 100 g | $65.00 $122.00 $428.00 $851.00 $1873.00 $4994.00 | 33 | |
Might inhibit CPA1 directly as a serine protease inhibitor. | ||||||